University of Miami hands over ibogaine application to US
Impact on your practice
While psychedelic-assisted therapy is emerging as a treatment modality, this development is primarily relevant to researchers and institutional providers rather than community-based therapists. The regulatory pathway for ibogaine remains unclear and unlikely to affect most therapy practices in the near term.
Key facts
University of Miami transferred its 1994 ibogaine IND application to federal government
Trump administration executive order in April aimed to accelerate psychedelic drug development for serious mental illness
Application transfer intended to give broader access to foundational FDA authorization
Ibogaine remains Schedule I controlled substance with limited clinical pathway
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
[MA] H4895: Expanding access to mental health services
This bill aims to expand mental health service access in Massachusetts and has cleared committee with a favorable recommendation. Depending on final language, it could affect reimbursement rates, telehealth authorization, or insurance coverage requirements.
[TN] SB1248: AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.
This comprehensive TN mental health bill touches multiple code sections and could affect licensure, scope of practice, insurance requirements, and workforce regulations. Therapists should monitor its progress closely as it moves through committee.
Advancing the Future of Behavioral Health Data Exchange
This policy direction addresses a critical pain point for therapists: the lack of integrated health data exchange with primary care and medical providers. Improved interoperability could reduce documentation burden, improve care coordination, and reduce liability from medication interactions or missed diagnoses. However, it may also increase compliance requirements and data security obligations.
Opinion: MAHA is rewriting the vocabulary of American mental health care
Federal deprescribing initiatives create new clinical and billing opportunities for therapists while potentially pressuring prescribing practices. Therapists should understand the evidence, reimbursement rules, and ethical considerations around medication tapering to protect clients and navigate changing clinical norms.